You're contacting media contact of this press release

Title: Fenbendazole for Breast Cancer Promising New Study

Imperial, MO, United States, 25th Feb 2025 - What if a drug you’d find in a vet’s office could double as a weapon against one of the deadliest forms of breast cancer? That’s the wild idea behind a new study spotlighting fenbendazole—a humble ant parasitic med that’s been keeping Fido worm-free for years. Published in Anticancer Research, this research is sparking curiosity about whether this low-key compound could take on triple-negative breast cancer (TNBC), a brutal diagnosis with limited treatment paths. The findings? Let’s just say they’re raising eyebrows.TNBC isn’t your average breast cancer. It’s a rogue player—fast-moving, stubborn, and missing the hormone receptors that let doctors target other types with precision drugs. For patients, that often means a grimmer outlook and a shorter playbook. So when scientists started poking around with fenbendazole, a dirt-cheap benzimidazole compound, they weren’t just thinking outside the box—they were raiding a whole different toolbox.The team ran their experiment with three cell types: MDA-MB-231 (a triple-negative troublemaker), MCF-7 (a milder breast cancer line), and MCF-10A (normal breast cells to keep things honest). They wanted to know: can fenbendazole pick a fight with cancer cells and leave the good guys alone? The answer’s a cautious “maybe”—but it’s a “maybe” with some serious punch.In the triple-negative MDA-MB-231 cells, fenbendazole unleashed chaos. It cranked up reactive oxygen species (ROS)—nasty little molecules that can stress cells to death. For these cancer cells, it was game over: their growth tanked, with a low IC50 showing they couldn’t handle the heat. The MCF-7 cells took a hit too, but not nearly as hard, suggesting fenbendazole might have a special grudge against TNBC’s unique makeup.Here’s the...

This press release is issued by King Newswire